One Dose Does Not Fit All: How Your Genes, Age, and Body Chemistry Determine Whether a Prescription Works for You

When a physician writes a prescription, the dose printed on that slip of paper is typically derived from large clinical trials—studies designed to identify what works for the average patient. But here is the inconvenient truth that rarely makes it into the exam room conversation: you may not be average. In fact, statistically speaking, very few people are.

The emerging field of pharmacogenomics—the study of how an individual's genetic makeup influences drug response—is reshaping the way forward-thinking clinicians and pharmacists approach dosing. What was once considered a "standard" prescription is increasingly recognized as a starting point, not a final answer.

Why Two Patients on the Same Drug Can Have Completely Different Experiences

Consider two patients, both 45 years old, both diagnosed with depression, and both prescribed the same selective serotonin reuptake inhibitor at the same dose. One feels markedly better within three weeks. The other experiences persistent nausea, insomnia, and no mood improvement after two months. Their prescriptions are identical. Their outcomes are not.

The explanation often lies in liver enzymes—specifically a family of proteins known as cytochrome P450 (CYP450) enzymes, which are responsible for metabolizing the majority of prescription medications in the human body. Genetic variants in genes such as CYP2D6, CYP2C19, and CYP3A4 can render a person a "poor metabolizer," meaning the drug accumulates to higher-than-intended concentrations, or an "ultrarapid metabolizer," meaning the drug clears the system so quickly that therapeutic levels are never achieved.

The FDA has acknowledged this reality for years. Dozens of drug labels now include pharmacogenomic information, and that number continues to grow. Yet in routine clinical practice across the United States, genetic-based dosing remains underutilized—largely because awareness among patients and even some providers has lagged behind the science.

The Role of Age: A Variable That Changes Everything

Genetics aside, age alone is a powerful modifier of drug metabolism. Older adults—particularly those over 65—represent the largest consumers of prescription medications in the U.S., yet they are frequently underrepresented in the clinical trials that establish dosing guidelines.

As the body ages, kidney function declines gradually, liver blood flow decreases, and the ratio of body fat to lean muscle shifts. Each of these changes affects how long a drug remains active in the system. A benzodiazepine prescribed at a standard adult dose may produce sedation lasting eight hours in a 35-year-old but linger dangerously in a 78-year-old with reduced renal clearance, increasing fall risk and cognitive impairment.

Pediatric patients present the opposite challenge. Children are not simply small adults. Their metabolic pathways develop at different rates, and weight-based dosing, while helpful, does not fully account for the developmental variability in enzyme activity between a toddler and a ten-year-old.

Body Composition: More Than a Number on the Scale

Body weight is commonly used as a dosing proxy, but it is an imprecise one. What matters more in many cases is lean body mass—the weight attributable to muscle, bone, and organs rather than adipose tissue. Fat-soluble medications distribute widely into fatty tissue, which can both delay their onset and prolong their effect. A patient with obesity may require dose adjustments not because they are heavier, but because the volume of distribution of a fat-soluble compound changes substantially.

This distinction becomes clinically significant with drugs like certain anesthetics, some antibiotics, and lipid-lowering medications. Pharmacists trained in clinical dosing calculations routinely account for these factors, though the adjustment does not always make it into a standard prescription generated by an electronic health record system.

Organ Function: The Overlooked Gatekeeper

Beyond genetics and body composition, the functional capacity of the kidneys and liver serves as a critical gating mechanism for drug clearance. Patients with chronic kidney disease, for example, may require substantially reduced doses of renally-cleared medications to avoid toxic accumulation. Similarly, impaired hepatic function—whether from cirrhosis, hepatitis, or other conditions—can dramatically slow the breakdown of drugs that rely on liver metabolism.

Routine prescribing does not always include a current assessment of these organ systems. Patients who develop kidney disease after a prescription is written may continue on a dose that was appropriate at initiation but has since become excessive. This is one reason pharmacists play an increasingly important role in ongoing medication management, not just dispensing.

Pharmacogenomic Testing: Moving From Reactive to Proactive

For decades, dose adjustments in clinical practice have largely been reactive—providers wait for a patient to report side effects or fail to respond, then modify the prescription accordingly. Pharmacogenomic testing offers a different model: anticipating how a patient will metabolize a medication before the first dose is taken.

Tests such as GeneSight, Genomind, and similar panels analyze multiple relevant genetic markers and provide clinicians with actionable guidance on which medications within a class are likely to be most effective—and at what dose range—for a specific individual. These panels are increasingly available through major health systems and independent laboratories, with some insurers now providing coverage, particularly for psychiatric medications.

The implications extend well beyond psychiatry. Cardiology, oncology, pain management, and anticoagulation therapy are all areas where pharmacogenomic data is actively influencing prescribing decisions. Warfarin dosing, for instance, is now supported by FDA labeling that references CYP2C9 and VKORC1 genetic variants as factors affecting appropriate dose ranges.

What Patients Can Do

For patients navigating complex medication regimens, the most actionable step is conversation. Asking a prescriber or pharmacist whether a pharmacogenomic test might be appropriate is a reasonable and increasingly welcomed question—particularly for individuals who have experienced unexplained side effects or inadequate responses to multiple medications.

It is also worth ensuring that any provider writing a new prescription has access to current lab values reflecting kidney and liver function, an accurate and complete medication list, and awareness of relevant supplements that may interact with CYP450 pathways.

The science of personalized medicine is no longer a distant promise. It is a clinical reality that, when applied thoughtfully, can meaningfully reduce trial-and-error prescribing and improve outcomes. The standard dose may be a reasonable place to start—but for many patients, it should not be the last word.